Home > Products > Tumor Cell Lines > Human Tumor Cell Lines >
NOMO-1 |
||||
|---|---|---|---|---|
| Product Name |
NOMO-1 |
|||
| Price | Get Quote | |||
| Product Code | Nomo-1; NOMO1 |
|||
| Cat.No |
ABC-TC1314 |
Species |
Human |
|
| Size/Quantity |
1 vial |
Biosafety Level |
1 |
|
| Shipping Info |
Dry Ice |
Storage |
Liquid Nitrogen |
|
| Description |
A human monocytic leukemia cell line, NOMO-1, was established from a female with acute monocytic leukemia (M5a). NOMO-1 exhibits promonocytic characteristics, and its differentiation into macrophage-like cells was induced by using 12-o-tetradecanoyl phorbol-13-acetate (TPA). Following the addition of TPA, fibronectin was observed in NOMO-1 cells, and the culture medium showed increased levels of Interleukin-1 (IL-1) α and IL-1 β.
Why choose NOMO-1 from AcceGen? NOMO-1, our cell product, underwent various tests and analyses to ensure its quality. We evaluated NOMO-1’s cell morphology and cell viability. Its growth performance was tested under culture conditions without antibiotics and antimycotics. Furthermore, we tested NOMO-1 for the absence of HIV-1, HIV-2, HBV, HCV, HTLV-1, and HTLV-2, as well as microbial contaminants such as fungi, bacteria, and mycoplasma. These rigorous assessments confirm the reliability and safety of NOMO-1 as a cell line for various applications. |
|||
| Disease | Acute Monocytic Leukemia |
|||
| Source Organ | Peripheral Blood |
|||
| Recommended Medium And Supplement | RPMI 1640 + 10% FBS |
|||
| Citation Guide |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID). |
|||
| Application | FOR RESEARCH USE ONLY NOMO-1 is a useful tool to study the differentiation and maturation of monocytes and identify AML-specific antigens for therapeutic targeting. NOMO-1, utilized as a model, exhibits aberrant expression of NANOG, an NKL homeobox gene that functions as a stem cell factor and is specifically expressed in hematopoietic progenitor cells. NOMO-1 is also employed in drug development and investigating potential signaling pathways. It expresses granulocyte colony-stimulating factor (G-CSF) and responds to exogenous G-CSF. In the NOMO-1 model, it has been observed that exogenous G-CSF increases sensitivity to DNA topoisomerase II-targeting drugs and upregulates the expression of transferrin receptor (TfR). Additionally, NOMO-1 serves as a valuable model for studying drug resistance. It has been confirmed to be resistant to pinometostat (EPZ-5676), a selective inhibitor of DOT1L. |
|||
| Growth Conditions | 37 ℃, 5% CO2 |
|||
| Product Type |
Human Leukemia Cell Lines |
|||
| Product Image |
|
|||
TPA also stimulated the secretion of tissue factors from NOMO-1 cells. TPA enhanced the secretion of tissue factor from NOMO-1 cells, while warfarin (1ng/ml) inhibited the secretion. Moreover, the activity of the plasminogen activator (PA) gradually increased during the 17-day culture period. NOMO-1 can be cultured in RPMI1640 medium with 10% FBS.- ONLINE INQUIRY
- PRODUCT REVIEWS
Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
